Shares of Natco Pharma were up over 1% on the Bombay Stock Exchange after the company alongwith Alvogen which had filed for generic versions of Tamilflu oral capsules (oseltamivir phosphate) in dosages of 30mg, 45mg and 75mg have settled the patent infringement suit filed by Gilead Sciences, Inc., Hoffmann-La Roche Inc., F. Hoffmann-La Roche Ltd. and Genentech, Inc., in New Jersey District Court.
The US Food and Drug Administration had granted approval to Natco for generic oseltamivir phosphate capsules on March 14, 2014, the company said in a release.
Under the terms of the settlement, Natco's partner Alvogen will be able to market the oseltamivir phosphate capsules before the expiration of the pediatric exclusivity period listed in FDA's Orange Book for U.S. Patent No. 5,763,483, which is February 23, 2017, the release added.
The stock opened at Rs 534 and touched a high of Rs 543. At 11:15am, over 330,000 shares were traded on both the stock exchanges.